Cellbxhealth PLC (CLBX)

Currency in GBP
1.70
-0.05(-2.86%)
Closed·
CLBX is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
1.631.78
52 wk Range
1.5017.44
Key Statistics
Bid/Ask
1.60 / 2.10
Prev. Close
1.75
Open
1.75
Day's Range
1.63-1.78
52 wk Range
1.5-17.44
Volume
377.12K
Average Volume (3m)
2.85M
1-Year Change
-83.81%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
CLBX Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
10.50
Upside
+517.65%
Members' Sentiments
Bearish
Bullish
ProTips
Holds more cash than debt on its balance sheet

Cellbxhealth PLC News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell

Cellbxhealth PLC Company Profile

CelLBxHealth plc, a medical diagnostic company, develops cancer diagnostics products in the United Kingdom, Europe, North America, and internationally. The company develops Parsortix PC1 systems, a medical device for the capture and harvest of intact circulating tumour cells (CTCs) from metastatic breast cancer patient blood for subsequent user-validated downstream analysis; and Parsortix PR1 system captures and harvests circulating tumour cells from blood. It also provides Portrait+ CTC Staining kit, a ready-to-use laboratory kit with analytical sensitivity and specificity for the identification, characterization, and enumeration of epithelial and mesenchymal circulating tumour cells; and CellKeep Slide, a CTC harvesting technology. In addition, the company offers laboratory services, including CTC enrichment and liquid biopsy analysis services; Portrait Flex, an immunofluorescence assay for the identification of epithelial, mesenchymal, and epithelial-to-mesenchymal transition; DNA damage response; Portrait PD-L1, evaluates CTCs; and custom CTC assays. CelLBxHealth plc has a strategic partnership with BioView Ltd to develop a human epidermal growth factor receptor 2 assay kit for breast cancer; and agreement with NuProbe USA, Inc. to use pan-cancer next generation sequencing (NGS) panel. The company was formerly known as ANGLE plc and changed its name to CelLBxHealth plc in October 2025. CelLBxHealth plc was founded in 1994 and is based in Guildford, the United Kingdom.

Compare CLBX to Peers and Sector

Metrics to compare
CLBX
Peers
Sector
Relationship
P/E Ratio
−0.3x−1.4x−0.6x
PEG Ratio
−0.010.030.00
Price/Book
0.5x1.0x2.6x
Price / LTM Sales
2.1x2.0x3.2x
Upside (Analyst Target)
-176.5%43.6%
Fair Value Upside
Unlock22.8%5.8%Unlock

Analyst Ratings

1 Buy
0 Hold
0 Sell
Ratings:
1 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 10.50
(+517.65% Upside)

Earnings

Latest Release
Sep 09, 2025
EPS / Forecast
-0.0287 / --
Revenue / Forecast
796.00K / --
EPS Revisions
Last 90 days

CLBX Income Statement

People Also Watch

158.60
CAML
-0.88%
3.80
KDNC
-10.59%
77.00
AVCT
-1.91%
570.00
BOOMA
-4.20%
8.71
MASTM
-13.76%

FAQ

What Stock Exchange Does Cellbxhealth Trade On?

Cellbxhealth is listed and trades on the London Stock Exchange stock exchange.

What Is the Stock Symbol for Cellbxhealth?

The stock symbol for Cellbxhealth is "CLBX."

What Is the Cellbxhealth Market Cap?

As of today, Cellbxhealth market cap is 5.47M.

What Is Cellbxhealth's Earnings Per Share (TTM)?

The Cellbxhealth EPS (TTM) is -0.05.

When Is the Next Cellbxhealth Earnings Date?

Cellbxhealth will release its next earnings report on 08 Sept 2025.

From a Technical Analysis Perspective, Is CLBX a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Cellbxhealth Stock Split?

Cellbxhealth has split 0 times.

How Many Employees Does Cellbxhealth Have?

Cellbxhealth has 119 employees.

What is the current trading status of Cellbxhealth (CLBX)?

As of 23 Nov 2025, Cellbxhealth (CLBX) is trading at a price of 1.70, with a previous close of 1.75. The stock has fluctuated within a day range of 1.63 to 1.78, while its 52-week range spans from 1.50 to 17.44.

What Is Cellbxhealth (CLBX) Price Target According to Analysts?

The average 12-month price target for Cellbxhealth is GBP10.5, with a high estimate of GBP11 and a low estimate of GBP10. 1 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +517.65% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.